Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indo US Bio-TechNSE:INDOUS +1.84%64 PS Ratio is 1.59 as of Jul. 18, 2026, which is 64% below its 10-year median of 4.43. GuruFocus rates NSE:INDOUS with a GF Score™ of 64/100 and a GF Value™ of ₹313.35 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 244 Agriculture companies, Indo US Bio-Tech ranks worse than 65.57% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Indo US Bio-Tech's share price is ₹87.28.
Indo US Bio-Tech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹55.02. Hence, Indo US Bio-Tech's PS Ratio for today is 1.59.
Good Sign:
Indo US Bio-Tech Ltd stock PS Ratio (=1.59) is close to 5-year low of 1.59.
The historical rank and industry rank for Indo US Bio-Tech's PS Ratio or its related term are showing as below:
NSE:INDOUS'
s PS Ratio Range Over the Past 10 Years
Min: 1.56 Med: 4.43 Max: 13.73
Current: 1.59
During the past 13 years, Indo US Bio-Tech's highest PS Ratio was 13.73. The lowest was 1.56. And the median was 4.43.
NSE:INDOUS's PS Ratio is ranked worse than 65.57% of 244
companies
in the Agriculture industry
Industry Median: 0.93
vs NSE:INDOUS: 1.59
Indo US Bio-Tech Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Indo US Bio-Tech was 6.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 19.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 13.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.80% per year.
During the past 13 years, Indo US Bio-Tech's highest 3-Year average Revenue per Share Growth Rate was 28.70% per year. The lowest was -1.30% per year. And the median was 17.50% per year.
Back to Basics: PS Ratio
Indo US Bio-Tech (NSE:INDOUS) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Indo US Bio-Tech PS Ratio Related Terms
Indo US Bio-Tech PS Ratio Historical Data
* Premium members only.
The historical data trend for Indo US Bio-Tech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Agricultural Inputs subindustry, Indo US Bio-Tech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo US Bio-Tech PS Ratio vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Indo US Bio-Tech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Indo US Bio-Tech's Share Price of today is ₹87.28. Indo US Bio-Tech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹55.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Indo US Bio-Tech (NSE:INDOUS) has a PS Ratio of 1.59 as of Jul. 18, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Indo US Bio-Tech and its competitors. This is 64% below median its historical median of 4.43. Over the past decade, Indo US Bio-Tech's PS Ratio has ranged from 1.56 to 13.73. According to the industry distribution chart, Indo US Bio-Tech ranks #160 out of 244 companies in the Agriculture industry, placing it in the top 65.6%.
Is Indo US Bio-Tech's PS Ratio too high?
Indo US Bio-Tech's current PS Ratio of 1.59 is 64% below median its 10-year median of 4.43. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 13.73. The Agriculture industry median PS Ratio is 0.93. Indo US Bio-Tech's value of 1.59 is 71% above this industry median. Based on the distribution chart, Indo US Bio-Tech ranks #160 out of 244 companies in the Agriculture industry, which is below the industry midpoint. Overall, Indo US Bio-Tech has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's PS Ratio compare to CTVA and CF?
According to the Agriculture industry distribution chart, Indo US Bio-Tech ranks #160 out of 244 companies for PS Ratio. This places Indo US Bio-Tech in the lower half of its industry. The industry median PS Ratio is 0.93. Indo US Bio-Tech's value of 1.59 is 71% above this benchmark. Historically, Indo US Bio-Tech's own PS Ratio has ranged from 1.56 to 13.73 over the past decade. While the company's 10-year median is 4.43 vs. the industry median of 0.93, Indo US Bio-Tech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for an Agriculture company?
The median PS Ratio among Agriculture companies is 0.93, based on 244 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo US Bio-Tech's current PS Ratio of 1.59 is 71% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Indo US Bio-Tech and its competitors. For the Agriculture industry, the median PS Ratio is 0.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo US Bio-Tech's current PS Ratio is 1.59, which is 64% below median its own 10-year median of 4.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹313.35, compared to a current price of ₹87.28 — trading 72.1% below its estimated fair value. The current PS Ratio is 1.59, which is 64% below median its 10-year median of 4.43 and 71% above the Agriculture industry median of 0.93. Indo US Bio-Tech's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current PS Ratio is 1.59 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?
Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued.
The current stock price of ₹87.28 is trading 72.1% below its estimated GF Value™ of ₹313.35.
GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.
Key valuation signals for NSE:INDOUS:
PS Ratio: 1.59 (64% below median its 10-year median of 4.43)
GF Value™: ₹313.35 vs. price of ₹87.28 (72.1% below fair value)
Industry Position: 71% above the Agriculture median (#160 of 244)
No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
64GF Score
Get the complete analysis for NSE:INDOUS
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOUS has been successfully added to your 
